文献速递核素与放射性配体治疗

177Lu-3BP-227用于神经降压素受体1靶向治疗转移性胰腺腺癌:首次临床结果

177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results.
PubMed 文献 · J Nucl Med · 2017-10-12

本研究纳入6例已无其他治疗选择的经证实的导管胰腺腺癌患者,接受新型神经降压素受体1(NTR1)拮抗剂177Lu-3BP-227用于评估NTR1体内表达,其中3例接受5.1-7.5 GBq的治疗活度。所有患者耐受良好,肾脏为剂量限制器官,最严重不良事件为可逆的2级贫血;1例患者达到部分缓解,症状和生活质量显著改善,自诊断存活13个月,自开始177Lu-3BP-227治疗存活11个月。结论认为本初步报告提供了使用177Lu-3BP-227治疗导管胰腺腺癌可行性的临床证据。

要点

  • 6例经证实的导管胰腺腺癌患者接受177Lu-3BP-227评估NTR1体内表达,其中3例接受5.1-7.5 GBq治疗活度。
  • 所有患者耐受良好,肾脏为剂量限制器官,最严重不良事件为可逆的2级贫血。
  • 1例患者达到部分缓解,症状和生活质量显著改善,自诊断存活13个月,自治疗开始存活11个月。

核心结论

  • 本初步报告提供了使用177Lu-3BP-227治疗导管胰腺腺癌可行性的临床证据。

研究设计与样本

  • 6例经证实的导管胰腺腺癌患者,均已耗尽所有其他治疗选择,接受新型NTR1拮抗剂177Lu-3BP-227用于评估NTR1体内表达。
  • 其中3例患者接受5.1-7.5 GBq的治疗活度。

主要发现

  • 所有患者对177Lu-3BP-227给药耐受良好。
  • 肾脏被确定为剂量限制器官。
  • 最严重的不良事件为可逆的2级贫血。
  • 1例患者达到部分缓解,并经历症状和生活质量的显著改善;该患者自诊断存活13个月,自开始177Lu-3BP-227治疗存活11个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers, with a very poor prognosis. Eligible patients were offered salvage radiopharmaceutical therapy with the novel NTR1 antagonist 177Lu-3BP-227. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received 177Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities of 5.1-7.5 GBq. Results: Administration of 177Lu-3BP-227 was well tolerated by all patients. The kidneys were identified as the dose-limiting organ. The most severe adverse event was reversible grade 2 anemia. One patient achieved a partial response and experienced significant improvement of symptoms and quality of life. This patient survived 13 mo from diagnosis and 11 mo from the start of 177Lu-3BP-227 therapy. Conclusion: This initial report provides clinical evidence of the feasibility of treatment of ductal pancreatic adenocarcinoma using 177Lu-3BP-227.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Baum RP, Singh A, Schuchardt C, et al. 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. J Nucl Med. 2017. PMID: 29025990. doi:10.2967/jnumed.117.193847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。